走进诺和诺德 更多 >>
诺和诺德是一家致力于人类健康、以先进的生物技术造福患者、医生和社会的世界领先生物制药公司。
诺和诺德公司的历史最早可追溯至1923年，80多年来一直是世界糖尿病研究和药物开发领域的主导。诺和诺德总部位于丹麦首都哥本哈根，现在全球79个国家设有分支机构，6个国家设有生产厂，截至08年底，员工超过 27，000名，销售遍及180个国家。
诺和诺德凭借自身的研发实力成为世界糖尿病治疗领域先导，在行业内拥有最为广泛的糖尿病治疗产品，其中包括最先进的胰岛素给药系统产品。
意大利Udine大学Antonio Ceriello教授
发布日期：2009-12-22 18:14 文章来源：丁香园
分享到：
关键词： 诺和锐
诺和诺德
novonordisk
Antonio
Ceriello
糖尿病
胰岛素
点击次数：
Antonio Ceriello
Udine, Italy
Antonio Ceriello is Professor of Endocrinology, in the Department of Pathology and Medicine at the University of Udine, Italy, and Adjunct Professor of Medicine at the University of Oklahoma.
Professor Ceriello is a member of the American Heart Association writing committee for guidelines on Acute Hyperglycemia and Acute Coronary Syndromes. He was also a consultant to the US National Institutes of Health for the 2003-2005 research
programme related to cardiovascular disease and type 1 diabetes. He is the President of the EASD Study Group on Diabetes and Cardiovascular Diseases and recently chaired the IDF committee for the development of guidelines to manage post-prandial glucose.
Professor Ceriello was the recipient of the 2004 EASD Castelli Pedroli Prize, and has published widely in the area of diabetes with over 200 original papers and several book chapters. He is also Associate Editor of Diabetes Care and Diabetic Medicine.
编辑: xiaoyan 作者:丁香园通讯员
以下网友留言只代表网友个人观点，不代表网站观点
